We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Analyses of the Rationale and Implementation of Research Biopsies in Oncology Clinical Trials at a Tertiary Cancer Center.
- Authors
OLYMPIOS, NATHALIE; COLLET, LAETITIA; PAESMANS, MARIANNE; JUNGELS, CHRISTIANE; KOTECKI, NURIA; AWADA, AHMAD; AFTIMOS, PHILIPPE
- Abstract
Background. Biomarkers in clinical trials have led to massive incorporation of research biopsies, with potentially risks and no direct benefit for patients. In 2018, the American Society of Clinical Oncology (ASCO) released an ethical framework to provide guidance on incorporating research biopsies in cancer clinical trials. Materials and Methods. We collected biopsy requirements of cancer clinical trials conducted at Institut Jules Bordet (IJB) between 2015 and 2019 to examine adherence with the ASCO Ethical Framework. We used logistic regression models to test the association between the request for biopsy, the request for tissue, and the adherence to the ASCO framework as well as some trial characteristics. Results. Between January 2015 and December 2019, 178 oncological studies were conducted at IJB. Of these, 138 (78%) were sponsored by industry, 132 (74%) were phase II and III studies, and 141 (79%) concerned metastatic disease. Tissue was required for inclusion for 119 (67%) studies, among which 59 required at least one new biopsy. Adherence to ASCO's Ethical Framework was 67% for studies requiring tissue and went down to 39% for studies requiring at least one new biopsy. In multivariate analysis, requests for tissue or new biopsies increased in early-phase studies (p < .001, p < .001, respectively) and in studies investigating innovative treatments (immunotherapy or targeted therapies; p < .01, p = .02). Compliance to the ASCO framework significantly decreased with time (p < .001) and in early-phase studies (p < .001). Conclusion. Numerous studies required tissue or new biopsies for exploratory objectives of unknown clinical utility. Requests for tissue increased over the years, whereas compliance to ASCO's Ethical Framework decreased.
- Subjects
BELGIUM; HOSPITALS; BIOPSY; CLINICAL trials; SPECIALTY hospitals; MULTIVARIATE analysis; TERTIARY care; METASTASIS; CANCER treatment; CONCEPTUAL structures; RESEARCH ethics; DESCRIPTIVE statistics; LOGISTIC regression analysis; STATISTICAL models; MEDICAL research; ONCOLOGY; AMERICAN Society of Clinical Oncology
- Publication
Oncologist, 2021, Vol 26, Issue 12, p1062
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1002/onco.13906